In October 2015, Sysmex was selected as the top company in the pharmaceuticals category in the 2015 Awards for Excellence in Corporate Disclosure, sponsored by the Securities Analysts Association of Japan. We also ranked first among the 213 companies in all industries evaluated for excellence in disclosure to individual investors. The principal reasons for these selections were as follows.
■Corporate Disclosure by Securities Analysts (Pharmaceuticals Category)
We were evaluated highly based on the judgment that the management team positions IR very highly, and its level of involvement in IR is high, as well as for the meaningful discussions that take place during briefings and at analyst meetings.
We also scored highly in terms of beneficial content of quarterly business results presentations and conference calls, the extensiveness of supplementary materials (financial data) and the useful content of technology presentations and facility tours.
■Provision of Information to Individual Investors
With regard to briefings for individual investors, we earned high marks for our website video distribution of the content of presentations and for explanations that are easy to understand and provided from an individual investor’s perspective.
Concerning our website, we were evaluated highly on having easy-to-understand descriptions of information that individual investors wish to know, as well as the inclusion of graphs and other materials that show operating performance trends in an easily understandable manner.
Our shareholder newsletter received a strong evaluation for its easy-to-understand explanations of our mid-term management plan vision and initiatives.
This was the fourth consecutive year Sysmex has been selected for excellence in disclosure.
Going forward, Sysmex will maintain its basic stance of ensuring fair, prompt, accurate and easy-to-understand disclosure. Furthermore, we will promote IR activities aimed at enhancing corporate value through two-way dialogue with shareholders and investors.
Note: Please refer to the Corporate Disclosure page of the Securities Analysts Association of Japan’s website for further details.